Fig. 3. Acylation of trastuzumab Fab fragment; (i) in its native form with: (a) NHS ester 1 (2.5 eq., pH 7.4, 4 °C, 16 h), (b) arylthioester 2 (10 eq., pH 7.4, 15 min, RT), (ii) pre-reduced (with TCEP) with: (c) NHS ester 1 (2.5 eq., pH 7.4, 22 °C, 1 h), (d) arylthioester 2 (10 eq., pH 7.4, 15 min, RT); 0, 1, 2, 3, 4 refer to the number of acyl groups added per species.
